Antidepressants for people with epilepsy and depression

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 12, 2014, Pages

  Maguire, Melissa J ^a   Weston, Jennifer ^b   Singh, Jasvinder ^c   Marson, Anthony G ^b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Clinical Psychology Service for Older People   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CITALOPRAM; DOXEPIN; NOMIFENSINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EPILEPSY; EPILEPTIC STATE; GASTROINTESTINAL SYMPTOM; HUMAN; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SEDATION; SEIZURE SCORE; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; ADOLESCENT; ADULT; CHEMICALLY INDUCED; CHILD; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; PROSPECTIVE STUDY; PSYCHOLOGY; QUALITY OF LIFE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; CHILD; DEPRESSION; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84925226186     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010682.pub2     Document Type: Review

References (58)

1. Hovorka J, Herman E, Nemcova I. Treatment of interictal depression with citalopram in patients with epilepsy. Epilepsy and Behavior 2000;1:444-7.
2. Kanner A, Kozak A, Frey M. The use of sertraline in patients with epilepsy: is it safe?. Epilepsy and Behavior 2000;1:100-5.
3. Kuhn K, Quednow B, Thiel M, Falkai P, Maier W, Elger C. Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy and Behavior 2003;4:674-9.
4. Li W, Ma D. A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression. Chinese Journal of Clinical Rehabilitation 2005;9(12):20-1.
5. Robertson M, Trimble M. The treatment of depression in patients with epilepsy: a double blind trial. Journal of Affective Disorders 1985;9:127-36.
6. Specchio L, Iudice A, Specchio N, La Neve A, Spinelli A, Galli R, et al. Citalopram as treatment of depression in patients with epilepsy. Clinical Neuropharmacology 2004;27(3):133-6.
7. Thome-Souza M, Kuczynski E, Valente K. Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy and Behavior 2007;10:417-25.
8. Zhu S, Luo L, Gui Y, et al. Short-term efficacy of venlafaxine treating the depression in epilepsy patients. Chinese Journal of Rehabilitation 2004;19(2):101.
9. Blumer D. Antidepressant and double antidepressant treatment for the affective disorder of epilepsy. Journal of Clinical Psychiatry 1997;58(1):3-11.
10. Gilliam F. Depression and health outcomes in refractory epilepsy. www.clinicaltrials.gov/ct/show/NCT00026637 2005.
11. Kocsis. Lexapro for major depression in patients with epilepsy. www.clinicaltrials.gov/ct/show/NCT01244724 2007.
12. Conrad E. Escitalopram treatment of major depression in patients with temporal lobe epilepsy. www.clinicaltrials.gov/ct/show/NCT00595699 2008.
13. Harmant J, Van Rijckevorsel-Harmant K, De Barsy T, Hendrickx B. Fluvoxamine: an antidepressant with low (or no) epileptogenic effect. Lancet 1990;336(8711):386.
14. Machado R, Espinosa A, Montoto A. Cholesterol concentrations and clinical response to sertraline in patients with epilepsy: preliminary results. Epilepsy & Behavior 2010;19:509-12.
15. Adams SJ, O'Brien TJ, Lloyd J, Kilpatrick CJ, Salzberg MR, Velakoulis D. Neuropsychiatric morbidity in focal epilepsy. British Journal of Psychiatry 2008;192(6):464-9. [PUBMED: 18515901]
16. Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biological Psychiatry 2007;62(4):345-54. [PUBMED: 17223086]
17. American Psychiatric Association. Diagnostic and Statistical Manual. 4th Edition. Washington DC: American Psychiatric Association, 2000.
18. Anhoury S, Brown RJ, Krishnamoorthy ES, Trimble MR. Psychiatric outcome after temporal lobectomy: a predictive study. Epilepsia 2000;41(12):1608-15.
19. Bagdy G, Kecskemeti V, Riba P, Jakus R. Serotonin and epilepsy. Journal of Neurochemistry 2007;100(4):857-73. [PUBMED: 17212700]
20. Baker G, Jacoby A, Chadwick D. The associations of psychopathology in epilepsy: a community study. Epilepsy Research 1996;25:29-39.
21. Barry JJ, Ettinger AB, Friel P, Gilliam FG, Harden CL, Hermann B, et al. Advisory Group of the Epilepsy Foundation as part of its Mood Disorder. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy & Behavior 2008;13(Suppl 1):S1-29.
22. Boylan LS, Flint LA, Labovitz DL, Jackson SC, Starner K, Devinsky O. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology 2004;62(2):258-61.
23. Cotterman-Hart S. Depression in epilepsy: why aren't we treating?. Epilepsy & Behavior 2010;19(3):419-21. [PUBMED: 20851689]
24. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551. [PUBMED: 21810886]
25. Dell'osso MC, Caserta A, Baroni S, Nisita C, Marazziti D. The relationship between epilepsy and depression: an update. Current Medicinal Chemistry 2013 Mar 15 [Epub ahead of print]. [PUBMED: 23521673]
26. Fiest KM, Dykeman J, Patten SB, Wiebe S, Kaplan GG, Maxwell CJ, et al. Depression in epilepsy: a systematic review and meta-analysis. Neurology 2013;80(6):590-9.
27. Gilliam FG. Diagnosis and treatment of mood disorders in persons with epilepsy. Current Opinion in Neurology 2005;18(2):129-33. [PUBMED: 15791142]
28. Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.for the GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
29. Hamid H, Kanner AM. Should antidepressant drugs of the selective serotonin reuptake inhibitor family be tested as antiepileptic drugs?. Epilepsy & Behavior 2013;26(3):261-5. [PUBMED: 23395350]
30. Hermann BP, Seidenberg M, Bell B. Psychiatric comorbidity in chronic epilepsy: identification, consequences, and treatment of major depression. Epilepsia 2000;41 Suppl 2:S31-41. [PUBMED: 10885738]
31. Hesdorffer DC, Hauser WA, Annegers JF, Cascino G. Major depression is a risk factor for seizures in older adults. Annals of Neurology 2000;47(2):246-9.
32. Hesdorffer DC, Hauser WA, Olafsson E, Ludvigsson P, Kjartansson O. Depression and suicide attempt as risk factors for incident unprovoked seizures. Annals of Neurology 2006;59(1):35-41. [PUBMED: 16217743]
33. Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: fire or false alarm?. Epilepsia 2009;50(5):978-86. [PUBMED: 19496806]
34. Hesdorffer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Annals of Neurology 2012;72(2):184-91. [PUBMED: 22887468]
35. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
36. Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ. Predictors of pharmacoresistant epilepsy. Epilepsy Research 2007;75(2-3):192-6.
37. Indaco A, Carrieri B, Naapi C, Gentile S, Striano S. Interictal depression in epilepsy. Epilepsy Research 1992;12:45-50.
38. Jacoby A, Baker G, Steen N, Potts P, Chadwick D. The clinical course of epilepsy and its psychological correlates: finding from a U.K. community study. Epilepsia 1996;37:148-61.
39. Kanner AM. Hippocampal atrophy: another common pathogenic mechanism of depressive disorders and epilepsy?. Epilepsy Currents 2011;11(5):149-50.
40. Kerr MP, Mensah S, Besag F, de Toffol B, Ettinger A, Kanemoto K, et al. International League of Epilepsy (ILAE) Commission on the Neuropsychiatric Aspects of Epilepsy. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia 2011;52(11):2133-8.
41. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. [PUBMED: 20156912]
42. Klerman G. Treatment of recurrent unipolar major depressive disorder. Commentary on the Pittsburgh study. Archives of General Psychiatry 1990;47(12):1158-61.
43. Kondziella D, Asztely F. Don't be afraid to treat depression in patients with epilepsy!. Acta Neurologica Scandinavica 2009;119(2):75-80. [PUBMED: 18759799]
44. Lambert M, Robertson M. Depression in epilepsy: etiology, phenomenology, and treatment. Epilepsia 1999;40(Suppl 10):s21-s47.
45. Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet 2012;380(9848):1180-92. [PUBMED: 23021287]
46. Maguire MJ, Hemming K, Hutton JL, Marson AG. Overwhelming heterogeneity in systematic reviews of observational anti-epileptic studies. Epilepsy Research 2008;80:201-212.
47. Mendez M, Cummings J, Benson D. Depression in epilepsy: significance and phenomenology. Archives of Neurology 1986;43:766-70.
48. Mula M, Schmitz B. Depression in epilepsy: mechanisms and therapeutic approach. Therapeutic Advances in Neurological Disorders 2009;2(5):337-44. [PUBMED: 21180624]
49. Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia 2013;54(1):199-203. [PUBMED: 22994856]
50. Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. Journal of Clinical Psychiatry 1992;53(5):160-2. [PUBMED: 1592842]
51. Sackeim HA, Roose SP, Lavori PW. Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD). Biological Psychiatry 2006;59(6):483-92. [PUBMED: 16517241]
52. Stahl SM. Blue genes and the mechanism of action of antidepressants. Journal of Clinical Psychiatry 2000;61(3):164-5. [PUBMED: 10817098]
53. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. Journal of Clinical Epidemiology 2000;53(11):1119-29. [PUBMED: 11106885]
54. Taylor RS, Sander JW, Taylor RJ, Baker GA. Predictors of health-related quality of life and costs in adults with epilepsy: a systematic review. Epilepsia 2011;52(12):2168-80.
55. Tellez-Zenteno JF, Patten SB, Jette N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007;48(12):2336-44. [PUBMED: 17662062]
56. Trimble MR. New antiepileptic drugs and psychopathology. Neuropsychobiology 1998;38(3):149-51. [PUBMED: 9778603]
57. Wroblewski BA, McColgan K, Smith K, Whyte J, Singer WD. The incidence of seizures during tricyclic antidepressant drug treatment in a brain-injured population. Journal of Clinical Psychopharmacology 1990;10(2):124-8. [PUBMED: 2341586]
58. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006;63(8):856-64. [PUBMED: 16894061]